Clinical trial

A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab

NCT03409458

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2018-04-24

PhasePHASE1 / PHASE2

Study timeline

Study start (actual)2018-04-24Date precision: day

Registry last updated2023-11-18

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Non-Small Cell Lung Cancer (NSCLC)unresolved

Interventions

PT-112DRUG

avelumabBIOLOGICAL

Sponsors & collaborators

Promontory Therapeutics Inc.lead sponsor

Pfizercollaborator

EMD Seronocollaborator

Mapped research locations

HoustonTexas, United States1 PhoenixArizona, United States1 JacksonvilleFlorida, United States1 AuroraColorado, United States1 RochesterMinnesota, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03409458 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.